BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

FDA Cautions Doctors On Eczema Treatment


10/19/2005 5:12:59 PM

The Food and Drug Administration issued an advisory to doctors Thursday urging caution in prescribing two drugs for eczema because of the possibility of cancer. The drugs Elidel and Protopic will receive new label warnings pointing out that an increased risk of cancer may be associated with their use, the agency said. Elidel and Protopic are applied to the skin to control eczema by suppressing the immune system. But animal tests have shown an increase in cancer associated with the drugs, and a small number of cancers have been reported in children and adults treated with the drugs, FDA (news - web sites) said in its advisory. The FDA said the manufacturers of the products have agreed to do further tests to determine the actual risk. Makers of the drugs contended that the products have not been tied to cancer. Fujisawa Healthcare Inc., maker of Protopic, released a letter it sent to physicians Feb. 24 saying concerns were based on animal studies and that its research indicates no increase in the rates of lymphoma or skin cancer in users of the drug. Novartis Pharmaceuticals, which makes Elidel, issued a statement saying it agrees that the product should be used as indicated but that adding a strong new warning is not justified.

Read at Reuters
Read at BBC News
Read at AP
Read at WebMD

Reuters
BBC News
AP
WebMD
   
Eczema

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES